[go: up one dir, main page]

NO20091659L - Fremgangsmater for behandling av disruptive oppforselsforstyrrelser - Google Patents

Fremgangsmater for behandling av disruptive oppforselsforstyrrelser

Info

Publication number
NO20091659L
NO20091659L NO20091659A NO20091659A NO20091659L NO 20091659 L NO20091659 L NO 20091659L NO 20091659 A NO20091659 A NO 20091659A NO 20091659 A NO20091659 A NO 20091659A NO 20091659 L NO20091659 L NO 20091659L
Authority
NO
Norway
Prior art keywords
disruptive behavior
behavior disorders
procedures
treatment
disorder
Prior art date
Application number
NO20091659A
Other languages
English (en)
Inventor
Magali Haas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20091659L publication Critical patent/NO20091659L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives en fremgangsmåte for behandling av disruptive oppførselsforstyrrelser inkludert både "Conduct Disorder" og "Oppositional Defiant Disorder" omfattende administrering til et individ som trenger det av en terapeutisk effektiv mengde av én eller flere karbamatforbindelser med formel 1 og/eller formel 2 Det beskrives videre en fremgangsmåte for behandling av disruptive oppførselsforstyrrelser inkludert både "Conduct Disorder" og "Oppositional Defiant Disorder", som inkluderer monoterapi og alternativt koterapi med minst et ytterligere psykoaktivt medisinsk virkestoff.
NO20091659A 2006-10-27 2009-04-27 Fremgangsmater for behandling av disruptive oppforselsforstyrrelser NO20091659L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86313706P 2006-10-27 2006-10-27
PCT/US2007/081048 WO2008070277A2 (en) 2006-10-27 2007-10-11 Methods for treating disruptive behavior disorders

Publications (1)

Publication Number Publication Date
NO20091659L true NO20091659L (no) 2009-05-26

Family

ID=39469514

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091659A NO20091659L (no) 2006-10-27 2009-04-27 Fremgangsmater for behandling av disruptive oppforselsforstyrrelser

Country Status (19)

Country Link
US (1) US20080103127A1 (no)
EP (1) EP2089015B1 (no)
JP (1) JP2010508279A (no)
KR (1) KR20090088379A (no)
CN (1) CN101646432A (no)
AT (1) ATE489083T1 (no)
AU (1) AU2007329779A1 (no)
BR (1) BRPI0718318A2 (no)
CA (1) CA2667510A1 (no)
CO (1) CO6160292A2 (no)
DE (1) DE602007010818D1 (no)
EA (1) EA015690B1 (no)
ES (1) ES2354319T3 (no)
IL (1) IL198396A0 (no)
MX (1) MX2009004552A (no)
NO (1) NO20091659L (no)
SV (1) SV2009003241A (no)
WO (1) WO2008070277A2 (no)
ZA (1) ZA200903652B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
KR100758609B1 (ko) * 1999-08-20 2007-09-13 오르토-맥네일 파마슈티칼, 인코퍼레이티드 트라마돌 화합물 및 항경련 약물을 포함하는 조성물
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
IL157594A0 (en) * 2001-02-27 2004-03-28 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating anxiety disorders

Also Published As

Publication number Publication date
AU2007329779A1 (en) 2008-06-12
CA2667510A1 (en) 2008-06-12
BRPI0718318A2 (pt) 2013-11-26
WO2008070277A3 (en) 2008-08-07
KR20090088379A (ko) 2009-08-19
EA015690B1 (ru) 2011-10-31
MX2009004552A (es) 2009-11-10
CO6160292A2 (es) 2010-05-20
SV2009003241A (es) 2010-04-15
ES2354319T3 (es) 2011-03-14
ATE489083T1 (de) 2010-12-15
WO2008070277A2 (en) 2008-06-12
US20080103127A1 (en) 2008-05-01
CN101646432A (zh) 2010-02-10
DE602007010818D1 (de) 2011-01-05
EA200970425A1 (ru) 2009-12-30
EP2089015A2 (en) 2009-08-19
EP2089015B1 (en) 2010-11-24
IL198396A0 (en) 2010-02-17
ZA200903652B (en) 2010-08-25
JP2010508279A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
BRPI0408784A (pt) método para usar um composto
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
DK1742624T3 (da) Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
CL2007003827A1 (es) Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
NO20091659L (no) Fremgangsmater for behandling av disruptive oppforselsforstyrrelser
NO20092018L (no) Fremgangsmater for a behandle depresjon
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2005097122A3 (en) Method of treating schizophrenia and/or glucoregulatory abnormalities
EA200870088A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови
NO20064964L (no) Behandling av svekket respiratorisk funksjon
WO2009054957A3 (en) Methods for diagnosis and treatment of chronic fatigue syndrome
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2009154800A3 (en) Compositions and methods for treating lung disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application